

Please type a plus sign (+) inside this b

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Use as many sheets as necessary

Sheet

of

6

Application Number 09/801,933
Filing Date March 7, 2001
First Named Inventor Bookser
Group Art Unit 1614
Examiner Name TBA
Attorney Docket Number 030727.0042.CIP1

JAN 31 2002

RECEIVED
JAN 31 2002
TECH CENTER 1801/2900

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
TC	AA	3,524,846		Moffat, et al.	10/20/70	
	AB	4,968,790		DeVries, et al.	11/6/90	
	AC	5,157,027		Biller, et al.	10/20/92	
	AD	5,658,889		Gruber, et al.	08/19/97	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
TC	AE	EP	0 427 799		GENSIA PHARMACEUTICALS, INC.	11/30/1994		
	AF	EP	0 632 048		MITSUBISHI KASEI CORPORATION	01/4/1995		
	AG	WO	00/14095		METABASIS THERAPEUTICS, INC.	03/16/2000		
	AH	WO	00/38666		METABASIS THERAPEUTICS, INC.	07/06/2000		
	AI	WO	00/52015		METABASIS THERAPEUTICS, INC.	09/08/2000		
	AJ	WO	90/08155		BOARD OF REGENTS, UNIV. OF TEXAS SYSTEM	07/26/1990		
	AK	WO	90/10636		BOARD OF REGENTS, UNIV. OF TEXAS SYSTEM	09/20/1990		
	AL	WO	91/19721		GLAZIER, A.	12/26/1991		
	AM	WO	95/07920		GILEAD SCIENCES, INC.	03/23/1995		
	AN	WO	98/39342		METABASIS THERAPEUTICS, INC.	09/11/1998		
	AO	WO	98/39343		METABASIS THERAPEUTICS, INC.	09/11/1998		
	AP	WO	98/39344		METABASIS THERAPEUTICS, INC.	09/11/1998		

Examiner Signature

Date Considered

11/20/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

of

6

Complete if Known

Application Number	09/801,933
Filing Date	March 7, 2001
First Named Inventor	Bookser
Group Art Unit	1614
Examiner Name	TBA
Attorney Docket Number	030727.0042.CIP1

NON-PATENT LITERATURE DOCUMENTS

	AQ	ALEXANDER, et al., "Preparation of 9-(2-Phosphonomethoxyethyl)adenine Esters as Potential Prodrugs," <u>Collect. Czech. Chem. Commun.</u> , 59:1853-1869 (1994)
	AR	ATHMANI, et al., "Azoles. Part 9. ¹ Synthesis of Derivatives of Thieno[2,3-d]thiazole, 4H-Pyrrolo-[2,3-d]thiazole, 2H-Pyrazolo[3,4-d]thiazole from Thiazolidine-2,4-dione." <u>J. Chem. Soc., Perkin Trans. 1</u> , 973-977 (1992)
	AS	BARLUENGA, et al., "Substituted Organolithium Compounds. New Reagents for Synthesis," <u>J. Org. Chem.</u> , 44(26):4798-4801 (1979)
	AT	BENZARIA, et al., "Synthesis <i>in vitro</i> Antiviral Evaluation, and Stability Studies of Bis(S-acyl-2-thioethyl) Ester Derivatives of 9-[2-(Phosphonomethoxy)ethyl]adenine (PMEA) as Potential PMEA Prodrugs with improved Oral Bioavailability," <u>J. Med. Chem.</u> , 39:4958-4965 (1996)
	AU	BHONGLE, et al., "Expedient and High-Yield Synthesis of Alkylphosphonyl Dichlorides Under Mild, Neutral Conditions: Reaction of Bis(Trimethylsilyl)Alkyl Phosphonates with Oxalyl Chloride/Dimethylformamide," <u>Synth. Commun.</u> , 17(9):1071-1076 (1987)
	AV	BRINTON, et al., "Characterization of Murine Caraparu <i>Bunyavirus</i> Liver Infection and Immunomodulator-Mediated Antiviral Protection," <u>Antiviral Res.</u> , 20:155-171 (1992)
	AW	CAMPAGNE, et al., "Synthesis of Mixed Phosphonate Diester Analogues of Dipeptides using BOP or PyBOP Reagents," <u>Tetrahedron Lett.</u> , 34:6743-6744 (1993)
	AX	CAMPBELL, et al., "The Synthesis of Phosphonate Esters, an Extension of the Mitsunobu Reaction," <u>J. Org. Chem.</u> , 57:6331-6335 (1992)
	AY	CANAS, et al., "Regioselective Ring Opening of Chiral Epoxyalcohols by Primary Amines," <u>Tetrahedron Lett.</u> , 32:6931-6934 (1991)
	AZ	CASARA, et al., "Synthesis of Acid Stable 5'-O-Fluoromethyl Phosphonates of Nucleosides. Evaluation as Inhibitors of Reverse Transcriptase," <u>Bioorg. Med. Chem. Lett.</u> , 2:145-148 (1992)

Examiner
Signature

Date
Considered

11/22/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

of

6

Complete if Known

Application Number	09/801,933
Filing Date	March 7, 2001
First Named Inventor	Bookser
Group Art Unit	1614
Examiner Name	TBA
Attorney Docket Number	030727.0042.CIP1

RECEIVED
JAN 31 2002
TECH CENTER 160018001

72	BA	CLAUS, et al., "Mechanism of the Acute Action of Insulin On Hepatic Gluconeogenesis," <u>Mechanisms of Insulin Action</u> , pp. 305-321, Elsevier Science, (1992)	
	BB	COMMERCON, et al., "Diastereoselective Chlorocyclofunctionalization of N-allylic Trichloroacetamides: Synthesis of an Analogue and Potential Precursor of RP49532," <u>Tetrahedron Lett.</u> , 31:3871-3874 (1990)	
	BC	COREY, et al., "Enantioselective and Practical Synthesis of R- and S-Fluoxetine," <u>Tetrahedron Lett.</u> , 30:5207-5210 (1989)	
	BD	CURRAN, "Thermolysis of Bis[2—[(trimethylsilyl)oxy]prop-2-yl] fuxoran (TOP-furoxan). The First Practical Method for Intermolecular Cycloaddition of an in Situ Nitrile Oxide with 1,2-Di and Trisubstituted Olefins, <u>J. Am Chem. Soc.</u> , 107:6023-6028 (1985)	
	BE	DE LOMBAERT, et al., "N-Phosphonomethyl Dipeptides and Their Phosphonate Prodrugs, a New Generation of Neutral Endopeptidase (NEP, EC 3.4.24.11). Inhibitors," <u>J. Med. Chem.</u> , 37:498-511 (1994)	
	BF	DICKSON, et al., "Orally Active Squalene Synthase Inhibitors: Bis(acyloxy) Prodrugs of the α -Phosphonosulfonic Acid Moiety," <u>J. Med. Chem.</u> , 39:661-664 (1996)	
	BG	EGRON, et al., "Synthesis and Anti-HIV Activity of Some S-Acyl-2-Thioethyl (SATE) Phosphoramidate Derivatives of 3'-Azido-2',3'-Dideoxythymidine," <u>Nucleosides and Nucleotides</u> , 18:981-982 (1999)	
	BH	ELHADDADI, et al., "A Convenient Synthesis of Alkyl and Dialkyl 1-Benzyloxyamino Alkyl Phosphonates and Phosphinates," <u>Phosphorus, Sulfur and Silicon</u> , 54(1-4):143-150 (1990)	
	BI	FARQUHAR, et al., "Biologically Reversible Phosphate-Protective Groups," <u>J. Pharm. Sci.</u> , 72:324-325 (1983)	
	BJ	FERRES, H., "Pro-Drugs of β -Lactam Antibiotics," <u>Drugs of Today</u> , 19:499-538 (1983)	
	BK	FOLSOM, et al., "Relation of Carotid artery Wall Thickness to Diabetes Mellitus, Fasting Glucose and Insulin, Body Size, and Physical Activity," <u>Stroke</u> , 25:66-73 (1994)	

Examiner
Signature

Date
Considered

11/22/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

of

6

Application Number 09/801,933
Filing Date March 7, 2001
First Named Inventor Bookser
Group Art Unit 1614
Examiner Name TBA
Attorney Docket Number 030727.0042.CIP1

BL	FREED, et al., "Evidence for Acyloxymethyl Esters of Pyrimidine 5'-Deoxyribonucleotides as Extracellular Sources of Active 5'-Deoxyribonucleotides in Cultured Cells," <u>Biochem. Pharmacol.</u> , 38:3193-3198 (1989)
BM	HADDAD, et al., "Stereocontrolled Reductive Amination of 3-Hydroxy Ketones," <u>Tetrahedron Lett.</u> , 38:5981-5984 (1997)
BN	HOFFMANN, M., "A Simple, Efficient Synthesis of Dibenzyl and Di-p-nitroben 1-Hydroxyalkanephosphonates," <u>Synthesis</u> , pp. 62-64 (1988)
BO	HORI, et al., "Palladium (II)-Catalyzed Asymmetric 1,3-Dipolar Cycloaddition of Nitrones to 3-Alkenoyl-1,3-oxazolidin-2-ones," <u>J. Org. Chem.</u> , 64:5017-5023 (1999)
BP	HOWARD, G. et al., "Insulin Sensitivity and Atherosclerosis," <u>Circulation</u> , 93:1809-1817 (1996)
BQ	IYER, et al., "Synthesis of Acyloxyalkyl Acylphosphonates as Potential Prodrugs of the Antiviral, Trisodium Phosphonoformate (Foscarnet Sodium)," <u>Tetrahedron Lett.</u> , 30:7141-7144 (1989)
BR	KHAMNER, et al., "Neighboring Group Catalysis in the Design of Nucleotide Prodrugs," <u>J. Med. Chem.</u> , 39:4109-4115 (1996)
BS	KOZUMI, et al., "Complete Regio- and Stereospecificity in the Lewis Acid Catalyzed Diels-Alder Reactions of (Z) 2-Methoxy-1(phenylthio)-1,3-butadienes. Conversion of the CS Configuration of an Adduct to the CC Configuration at the Allylic Position by a [2,3] Sigmatropic Rearrangement," <u>J. Org. Chem.</u> , 47:4005-4008 (1982)
BT	MARTIN, et al., "Synthesis and Antiviral Activity of Various Esters of 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine," <u>J. Pharm. Sci.</u> , 76(2):180-184 (1987)
BU	MARYANOFF, "Stereoselective Synthesis and Biological Activity of β - and α -D-Arabinose 1,5-Diphosphate: Analogues of a Potent Metabolic Regulator," <u>J. Am. Chem. Soc.</u> , 106:7851-7853 (1984)
BU-A	McGUIGAN, et al., "Synthesis and Anti-HIV Activity of Some Haloalkyl Phosphoramidate Derivatives of 3'-Azido-3'-Deoxythymidine (AZT): Potent Activity of the Trichloroethyl Methoxyalaninyl Compound," <u>Antiviral Research</u> , 15, 255-263 (1991)
BU	MEIER, C., et al., "Cyclic Saligenyl Phosphotriesters of 2',3'-Dideoxy-2',3'-didehydrothymidine (d4T) - A New Pro-Nucleotide Approach," <u>Bioorg. Med. Chem. Lett.</u> , 7:99-104 (1997)

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

of

6

Complete if Known

Application Number	09/801,933
Filing Date	March 7, 2001
First Named Inventor	Bookser
Group Art Unit	1614
Examiner Name	TBA
Attorney Docket Number	030727.0042.CIP1

RECEIVED
JAN 31 2002
TECH CENTER 1600/2901

BW	MITCHELL, et al., "Bioreversible Protection for the Phospho Group: Bioactivation of the Bi(4-acyloxybenzyl) and Mono(4-acyloxybenzyl) Phosphoesters of Methylphosphonate and Phosphonoacetate," <u>J. Chem. Soc., Perkin Trans. 1</u> , 38:2345-2353 (1992)
BX	MITSUNOBO, et al., "The Use of Diethyl Azodicarboxylate and Triphenylphosphine in Synthesis and Transformation of Natural Products," <u>Synthesis</u> , pp. 1-28 (1981)
BY	MUKAIYAMA, et al., "Synthesis of Oligothymidylates and Nucleoside Cyclic Phosphates by Oxidation-Reduction Condensation," <u>J. Am. Chem. Soc.</u> , 94:8528-8532 (1972)
BZ	NISHIMURA, et al., "Orally Active 1-(Cyclohexyloxycarbonyloxy)Alkyl Ester Prodrugs of Cefotiam," <u>J. Antibiot.</u> , 40(1):81-90 (1987)
CA	OHASHI, et al., "Synthesis of Phosphonosphingoglycolipid Found in Marine Snail <u>Trubo Cornutus</u> ," <u>Tetrahedron Lett.</u> , 29:1189-1192 (1988)
CB	PATOIS, et al., "Easy Preparation of Alkylphosphonyl Dichlorides," <u>Bull. Soc. Chim. Fr.</u> , 130:485-487 (1993)
CC	PILKIS, et al., "Hormonal Regulation of Hepatic Gluconeogenesis and Glycolysis," <u>Ann. Rev. Biochem.</u> , 57:755-783 (1988)
CD	POSNER, et al., "3-Bromo-2-Pyrone: An Easily Prepared Chameleon Diene And A Synthetic Equivalent Of 2-Pyrone In Thermal Diels-Alder Cycloadditions," <u>Tetrahedron Lett.</u> , 39:5295-5298 (1991)
CE	PUECH, et al., "Intracellular Delivery of Nucleoside Monophosphates Through a Reductase-Mediated Activation Process," <u>Antiviral Res.</u> , 22:155-174 (1993)
CF	QUAST, et al., "Herstellng von Methylphosphonsaure-diclorid," <u>Synthesis</u> , pp. 461-538 (1974)
CG	RAO, et al., "Studies Directed Towards The Synthesis of Immunosuppressive Agent FK-506: Synthesis of the Entire Top-Half," <u>Tetrahedron Lett.</u> , 32:547-550 (1991)
CI	REGEN, et al., "Sensitivity of Pathway Rate to Activities of Substrate-Cycle Enzymes: Application to Gluconeogenesis and Glycolysis," <u>J. Theor. Biol.</u> , 111:635-658 (1984)
CJ	SERAFINOWSKA, et al., "Synthesis and <i>in Vivo</i> Evaluation of Prodrugs of 9-[2-(Phosphonomethoxy)ethoxy]adenine," <u>J. Med. Chem.</u> , 38:1372-1379 (1995)


Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box +

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/801,933
Filing Date	March 7, 2001
First Named Inventor	Bookser
Group Art Unit	1614
Examiner Name	TBA
Attorney Docket Number	030727.0042.CIP1

Sheet

of

6

CK	SHAW, et al., "Metabolism and Pharmacokinetics of Novel Oral Prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in Dogs," <u>Pharm. Res.</u> , 14:(12) 1824-1829 (1997)
CL	SHULMAN, et al., "Pathways of Glycogen Repletion," <u>Physiol. Rev.</u> , 72(4):1019-1035 (1992)
CM	SIDDIQUI, et al., "The Presence of Substituents on the Aryl Moiety of the Aryl Phosphoramidate Derivative of d4T Enhances Anti-HIV Efficacy in Cell Culture: A Structure Activity Relationship," <u>J. Med. Chem.</u> , 42:393-399 (1999)
CN	SRIVASTVA, et al., "Bioreversible Phosphate Protective Groups: Synthesis and Stability of Model Acyloxymethyl Phosphates," <u>Bioorg. Chem.</u> , 12:118-129 (1984)
CO	STARRETT, et al., "Synthesis, Oral Bioavailability Determination, and in Vitro Evaluation of Prodrugs of the Antiviral Agent 9-[2-(Phosphonomethoxy)ethyl]adenine (PMEA)," <u>J. Med. Chem.</u> , 37:1857-1864 (1994)
CP	STILL, et al., "Direct Synthesis of Z-Unsaturated Esters. A Useful Modification of the Horner-Emmons Olefination," <u>Tetrahedron Lett.</u> , 24:4405-4408 (1983)
CQ	STOWELL, et al., "The Mild Preparation of Synthetically Useful Phosphonic Dichlorides: Application to the Synthesis of Cyclic Phosphonic Diesters and Diamides," <u>Tetrahedron Lett.</u> , 31:3261-3262 (1990)
GR	U.K. Prospective Diabetes Group, U.K. Prospective Diabetes Study 16. "Overview of 6 Years' Therapy of Type II Diabetes: A Progressive Disease," <u>Diabetes</u> , 44:1249-1258 (1995)
CS	WIECZOREK, et al., "Plant-Growth-Regulating N-(Phosphonoacetyl)amines," <u>Pest. Sci.</u> , 40(1):57-62 (1994)
CT	ZBOROVSKII, et al., "Heterocyclization of Phenylethynylphosphonic Acid Under the Action of Selenium Dioxide or Hydrogen Bromide," <u>Russian J. Gen. Chem.</u> , 64(9):1401-1402 (1994)

Examiner
Signature

Date
Considered

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.